SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00570297

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Genetic Influences of Albuterol Response In Children With Bronchiolitis

Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children with asthma. We suspect that genetic variations of the β2-AR also affect response to β2-AR agonist therapy in children with bronchiolitis.

NCT00570297 Bronchiolitis
MeSH: Bronchiolitis
HPO: Bronchiolitis


Primary Outcomes

Description: The primary end point is change in lung resistance following a single dose of inhaled b2-AR agonist therapy (albuterol).

Measure: Change in lung resistance

Time: Immediate

Secondary Outcomes

Description: To assess the change in lung compliance following a single dose of inhaled b2-AR agonist therapy (albuterol)

Measure: Change in lung compliance

Time: Duration of hospitalization

Description: To compare duration of mechanical ventilation and ICU hospital length of stay by genotype

Measure: Comparison by genotype

Time: Duration of Hospitalization

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 E27Q

The next most common polymorphism of the β2-AR gene, glutamine to glutamic acid at position 27 (Glu27Gln), may be associated with the development of asthma and airway hyperresponsiveness, but these relationships are less clear. --- Glu27Gln ---



HPO Nodes


HPO:
Bronchiolitis
Genes 7
SLC35C1 TAP1 PLEC PLCG2 SDCCAG8 TAP2 TAPBP